The incidence and prevalence of critical limb ischaemia (CLI) is progressively increasing, mainly because of the widespread incidence of diabetes mellitus and longer life expectancy in developed countries. 1 Beyond lifestyle changes and medical therapy, arterial revascularisation is a mainstay in the management of patients with CLI due to below-the-knee (BTK) disease in order to improve functional class and prevent complications possibly leading to amputation and limb loss. 2 Until recently vascular surgery by means of distal bypasses was considered the only feasible revascularisation option, 1,2 but the introduction of dedicated techniques and devices has shown that percutaneous arterial revascularisation by means of percutaneous transluminal angioplasty (PTA) is feasible and safe in these patients, with satisfactory clinical results. 3, 4 Furthermore, the landmark Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial indicates that a percutaneous revascularisation strategy is probably equivalent to bypass surgery in patients with CLI. 5 However, there remains room for improvement, as PTA may carry risks of suboptimal result, abrupt vessel closure or late restenosis or re-occlusion.
Stent implantation has proved highly beneficial in the coronary realm and, thanks also to the development of drug-eluting stents (DES), has become a standard for most percutaneous coronary interventions. Conversely, the role of stenting in peripheral artery disease is still debated, especially when the BTK district is considered. Indeed, only a few reports to date are available on BTK stenting (see Table 1 ), [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] with only one pertinent randomised trial supporting stenting versus standard PTA. 14 Among the concerns raised on the infragenicular use of stents are the risks of fracture, restenosis and thrombosis. Another major issue is the lack of dedicated and long stents able to treat the typical BTK lesion: a long and calcified segment often with diffuse occlusive disease.
Most recently, a dedicated device for BTK use has been developed: the Chromis Deep™ stent (Invatec, Roncadelle, Italy) (see Figures 1 and 2 ).
Engineered as a 'BTK-lesion-specific' stent to allow treatment of long diffusely diseased infrapopliteal vessel segments (as normally encountered in CLI patients), the Chromis Deep is a BTK-dedicated stent and delivery system. The stent consists of a cobalt-chromium balloonexpandable metallic platform with closed-cell design, thin struts, diameters ranging between 2.0 and 4.0mm and lengths spanning from 10 to 76 mm. The delivery system is a 0.014-inch guidewire-compatible balloon catheter based on the BTK-dedicated PTA balloon Amphirion DEEP™ (Invatec, Roncadelle, Italy). Chromis Deep is available in over-thewire designs, with shaft lengths of 120cm (for ipsilateral access) or 150cm (for contralateral access).
The aim of this retrospective study was to assess the safety and efficacy of the Chromis Deep stent in the treatment of patients with BTK disease following failed PTA.
Methods
We abstracted baseline procedural and follow-up data on all consecutive patients who underwent implantation of a Chromis Deep stent in our institution between June 2006 and September 2007. All patients gave written informed consent, and the retrospective study was conducted in accordance with the local ethics committee.
Patients with symptomatic peripheral artery disease (Rutherford category 3-6) underwent arterial angiography by means of ipsilateral or contrlateral access. 18 After angiographic documentation of infrapopliteal stenotic (>70% diameter reduction) or occlusive disease, PTA was attempted using dedicated guidewires and semi-compliant balloons, as per routine at our centre. Specifically, BTK-dedicated 0.014-inch guidewires and over-the-wire balloons were used to cross and dilate (12-14atm for two to three minutes) the diseased segments. 4 After retrieval of the balloon, digital subtraction angiography was performed to appraise post-PTA results. Stenting with the Chromis Deep was then considered only in cases of failed PTA, classified as persistent suboptimal angiographic result (residual diameter stenosis >50%) or flow-limiting dissection in a non-bending zone.
All patients were pre-treated with aspirin and/or clopidogrel and peri-procedurally managed with 70-100IU.kg of unfractioned heparin.
Post-procedurally, haemostasis was achieved either manually or with closure devices, 19 and both aspirin and clopidogrel were continued for at least four weeks.
A clinical follow-up visit was performed in all patients and included assessment of vital status and Duplex ultrasound imaging of the affected limb. In cases of lack of clinical improvement, clinical recurrence (e.g. foot ulcer) or ultrasound evidence of restenosis or re-occlusion, patients underwent repeat lower limb angiography, followed by revascularisation where appropriate.
The primary end-point of the study was limb salvage rate for patients with CLI and improvement of Rutherford classification for claudicant patients. 20 We also appraised the risk of major (above the ankle) and Table 4 ). Short, noncompliant balloons were also employed in cases of calcific or fibrotic lesions to optimally expand the stent.
All procedures were angiographically and clinically successful. After eight months (246±101 days) of follow-up, all patients showed clinical improvement in their functional status (see Tables 5 and 6 ): the median Rutherford class change was from 5 to 3 (p<0.01), with most patients Duplex ultrasound follow-up, completed in 20 patients (100%), showed that restenosis or re-occlusion had occurred in six (30%). All of these patients underwent angiographically and procedurally successful repeat percutaneous revascularisation with PTA angioplasty.
Discussion
This study, the first to date to report on this novel dedicated device for and stent thrombosis possibly due to slow flow. In addition, most patients with CLI have extensive and diffuse disease, and most available stents with infragenicular sizes (diameter between 2.0 and 4.0mm) are coronary stents and thus too short (usually 33mm or less) to adequately cover BTK lesions.
Despite these caveats, a number of studies are already available on BTK stenting (see Table 1 ). Data on the use of coronary-approved balloonexpandable bare-metal stents (BMS) in patients with CLI have been reported already by Feiring et al., 10 Morgan et al. 13 and Rand et al. for a total of 112 treated subjects. 14 
